<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607527</url>
  </required_header>
  <id_info>
    <org_study_id>CP-002, CP-003</org_study_id>
    <nct_id>NCT02607527</nct_id>
  </id_info>
  <brief_title>Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System</brief_title>
  <official_title>Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral&#xD;
      regurgitation in subjects determined appropriate for mitral valve surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral&#xD;
      regurgitation in subjects determined appropriate for mitral valve surgery.&#xD;
&#xD;
      This trial is designed in accordance with the 2014 ACC/AHA guidelines for valvular heart&#xD;
      disease, and the consensus statement of MVARC 2015.&#xD;
&#xD;
      Subjects will undergo transcatheter implantation of the Millipede IRIS implant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">January 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Safety defined as incidence of adverse events</measure>
    <time_frame>Procedure through 30 days post procedure</time_frame>
    <description>30 days defined as ability to implant, anchor and actuate without incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by reduction in mitral regurgitation without significant mitral stenosis as measured by echo</measure>
    <time_frame>Procedural through 48 hrs post procedure</time_frame>
    <description>Reduction in mitral regurgitation to optimal or acceptable levels without significant mitral stenosis post procedure (defined as discharge or 48 hrs whichever comes first) and EROA &lt;1.5 cm2 with transmitral gradient &lt;5mm Hg as compared to screening echo</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Device Implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transcatheter IRIS placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Valve IRIS Ring</intervention_name>
    <description>Transcatheter implantation of the IRIS</description>
    <arm_group_label>Device Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of symptomatic severe MR (effective regurgitant orifice (ERO) ≥0.2 cm2 for&#xD;
             Secondary MR, ERO ≥0.4 cm2 for Primary MR)&#xD;
&#xD;
          -  The New York Heart Association Functional Class II, III or ambulatory IV.&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) is ≥20% and ≤50%&#xD;
&#xD;
          -  Creatine Kinase-MB (CK-MB) obtained within prior 14 days &lt; local laboratory -Upper&#xD;
             Limit of Normal (ULN).&#xD;
&#xD;
          -  Left Ventricular End Systolic Dimension (LVESD) is ≤ 65 mm assessed by TTE obtained&#xD;
             within 90 days Exclusion Criteria: -Untreated clinically significant coronary artery&#xD;
             disease requiring revascularization.&#xD;
&#xD;
        Presence of any of the following:&#xD;
&#xD;
          -  Estimated pulmonary artery systolic pressure (PASP) &gt; 70 mmHg assessed by site based&#xD;
             on echocardiography or right heart catheterization&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or&#xD;
             any other structural heart disease causing heart failure other than dilated&#xD;
             cardiomyopathy of either ischemic or non-ischemic etiology&#xD;
&#xD;
          -  Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)&#xD;
&#xD;
          -  Hemodynamic instability requiring inotropic support or mechanical heart assistance.&#xD;
&#xD;
          -  Hemodynamic instability defined as systolic pressure &lt; 90 mmHg with or without&#xD;
             afterload reduction, cardiogenic shock or the need for inotropic support or&#xD;
             intra-aortic balloon pump or other hemodynamic support device.&#xD;
&#xD;
          -  Physical evidence of right-sided congestive heart failure with echocardiographic&#xD;
             evidence of moderate or severe right ventricular dysfunction.&#xD;
&#xD;
          -  Coronary artery bypass grafting (CABG) within 30 days prior to subject's consent.&#xD;
&#xD;
          -  Percutaneous coronary intervention within 30 days prior to subject's consent.&#xD;
&#xD;
          -  Tricuspid valve disease requiring surgery.&#xD;
&#xD;
          -  Aortic valve disease requiring surgery or TAVI.&#xD;
&#xD;
          -  Carotid surgery within 30 days prior to subject registration.&#xD;
&#xD;
          -  Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac -Resynchronization&#xD;
             Therapy with cardioverter-defibrillator (CRT-D) within the last 30 days prior to&#xD;
             subject registration.&#xD;
&#xD;
          -  Need for emergent or urgent surgery for any reason or any planned cardiac surgery&#xD;
             within the next 12 months.&#xD;
&#xD;
          -  Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve,&#xD;
             or any prior transcatheter mitral valve procedure.&#xD;
&#xD;
          -  Status 1 heart transplant or prior orthotopic heart transplantation.&#xD;
&#xD;
          -  Chronic Kidney Disease.&#xD;
&#xD;
          -  Chronic Steroid Therapy.&#xD;
&#xD;
          -  Cerebrovascular accident within 30 days prior to subject's consent.&#xD;
&#xD;
          -  Severe symptomatic carotid stenosis (&gt; 70% by ultrasound).Life expectancy &lt; 12 months&#xD;
             due to non-cardiac conditions.&#xD;
&#xD;
          -  Active infections requiring current antibiotic therapy.&#xD;
&#xD;
          -  Pregnant or planning pregnancy within next 12 months.&#xD;
&#xD;
          -  Currently participating in an investigational drug or another device study.&#xD;
&#xD;
          -  Severe organic lesions with mitral chords retraction, severely fibrotic and immobile&#xD;
             leaflets, severely deformed subvalvular apparatus.&#xD;
&#xD;
          -  endocarditis or active endocarditis in the last 3 months.&#xD;
&#xD;
          -  Heavily calcified annulus or leaflets, mitral valve stenosis.&#xD;
&#xD;
          -  Congenital malformation with limited valvular tissue&#xD;
&#xD;
          -  Patient requires mitral valve replacement&#xD;
&#xD;
          -  Previously implanted prosthetic mitral valve or annuloplasty ring/band.&#xD;
&#xD;
          -  Evidence of LV or LA thrombus, vegetation or mass&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction &lt;20%&#xD;
&#xD;
          -  Left Ventricular End Diastolic Diameter &gt;65 mm&#xD;
&#xD;
          -  Severe tricuspid regurgitation or severe RV dysfunction&#xD;
&#xD;
          -  Condition that prevents transatrial access or transfemoral access&#xD;
&#xD;
          -  Anatomical ineligibility to the investigational device&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to procedural or post procedural medication&#xD;
             (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or&#xD;
             titanium.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asunción</city>
        <zip>1023</zip>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

